Citizens Initiates Coverage On Bicara Therapeutics with Market Outperform Rating, Announces Price Target of $31
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Citizens analyst Reni J. Benjamin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform rating and announces Price Target of $31.
Citizens analyst Reni J. Benjamin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform rating and announces Price Target of $31.